anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To provide a cosmetic having excellent skin-beautifying effect and anti-suntan effect and containing a large amount of 4-hydroxycinnamic acid stably as an active component, by adding a weakly basic inorganic salt or weakly basic organic acid salt as a neutralizing agent. CONSTITUTION:A skin-beautifying and anti-suntan cosmetic containing (A) 0.1-20wt% (preferably 0.5-15%) 4-hydroxycinnamic acid and (B) a weakly basic inorganic salt or (C) a weakly basic organic acid salt. Although the component A has excellent melanine-suppressing activity, it is a crystal having low solubility in water and is hardly soluble also in general oil for cosmetic. A large amount of the compound A can be compounded stably to a cosmetic by adding 1-2mol of the compound B [e.g. MClO, MHCO3 or M2CrO4 (M is Na or K)] or component C (e.g. sodium acetate or potassium propionate) to 1mol of the component A.
PCT No. PCT/US95/09805 Sec. 371 Date Dec. 18, 1996 Sec. 102(e) Date Dec. 18, 1996 PCT Filed Aug. 2, 1995 PCT Pub. No. WO96/03984 PCT Pub. Date Feb. 15, 1996A method and devices for localized delivery of a chemotherapeutic agent to solid tumors, wherein the agent does not cross the blood-brain barrier and is characterized by poor bioavailability and/or short half-lives in vivo, are described. The devices consist of reservoirs which release drug over an extended period while at the same time preserving the bioactivity and bioavailability of the agent. In the most preferred embodiment, the device consists of biodegradable polymeric matrixes, although reservoirs can also be formulated from non-biodegradable polymers or reservoirs connected to implanted infusion pumps. The devices are implanted within or immediately adjacent the tumors to be treated or the site where they have been surgically removed.
Structural modifications of the superficial dermis during the aging process associated to alterations in the GAG- and PG profile appear to impact the quality of the dermal epidermal junction (DEJ). Previous biological and clinical evaluations of ER4017, a C-glycoside biomimetic of xylose, showed its capacity to stimulate GAG- and PG synthesis and to improve morphogenesis of the whole DEJ.

The aim of the study is to investigate the gene expression in human epidermis treated with ER4017 following sequential sellotapes strips after a 3 months ER4017 topical application. For this purpose, the modulation of gene expression is determined using a cDNA microarray technology. Stratum corneum disruption is performed following 3 months topical application on skin inner forearms. All the experiments are performed in 10 elderly healthy men. Volunteers are clinically and biophysically evaluated at baseline and then at monthly intervals or at 3 months respectively.
PURPOSE:The titled pharmaceutical composition, obtained by blending an antibiotic with cyclodextrin and collagen and having enhanced stability and absorbability of the antibiotic. CONSTITUTION:A pharmaceutical composition containing at least one selected from cyclodextrin and collagen and an antibiotic, e.g. cephaloridine or ce phazoline. The cyclodextrin is a nonreducing maltooligosaccharide in which D-glucose is linked in a ring form and a cavity is provided in the center of a cyclic structure. In some cases, the cyclodextrin forms a clathrate compound with a drug and stabilizes. The collagen is albuminoid accounting for a principal ingredient in the skin, bone, etc., of calves, etc., and an extract from the above- mentioned raw material is normally used as the collagen to be used in the composition. A phosphilipid is further preferably blended in composition and the cyclodextrin, collagen and phospholipid promote the absorption of the antibi otic. The local convergence of the antibiotic is further enhanced.
BACKGROUND: Sepsis survivors exhibit immune dysregulation that contributes to poor long-term outcomes. Phenotypic and functional alterations within the myeloid compartment are believed to be a contributing factor. Here we dissect the cellular and transcriptional heterogeneity of splenic CD11b+Ly6Chigh myeloid cells that are expanded in mice that survive the cecal ligation and puncture (CLP) murine model of polymicrobial sepsis to better understand the basis of immune dysregulation in sepsis survivors.
METHODS: Sham or CLP surgeries were performed on C57BL/6J and BALB/c mice. Four weeks later splenic CD11b+Ly6Chigh cells from both groups were isolated for phenotypic (flow cytometry) and functional (phagocytosis and glycolysis) characterization and RNA was obtained for single-cell RNA-seq (scRNA-seq) and subsequent analysis.
RESULTS: CD11b+Ly6Chigh cells from sham and CLP surviving mice exhibit phenotypic and functional differences that relate to immune function, some of which are observed in both C57BL/6J and BALB/c strains and others that are not. To dissect disease-specific and strain-specific distinctions within the myeloid compartment, scRNA-seq analysis was performed on CD11b+Ly6Chigh cells from C57BL/6J and BALB/c sham and CLP mice. Uniform Manifold Approximation and Projection from both strains identified 13 distinct clusters of sorted CD11b+Ly6Chigh cells demonstrating significant transcriptional heterogeneity and expressing gene signatures corresponding to classical-monocytes, non-classical monocytes, M1- or M2-like macrophages, dendritic-like cells, monocyte-derived dendritic-like cells, and proliferating monocytic myeloid-derived suppressor cells (M-MDSCs). Frequency plots showed that the percentages of proliferating M-MDSCs (clusters 8, 11 and 12) were increased in CLP mice compared to sham mice in both strains. Pathway and UCell score analysis in CLP mice revealed that cell cycle and glycolytic pathways were upregulated in proliferating M-MDSCs in both strains. Notably, granule protease genes were upregulated in M-MDSCs from CLP mice. ScRNA-seq analyses also showed that phagocytic pathways were upregulated in multiple clusters including the classical monocyte cluster, confirming the increased phagocytic capacity in CD11b+Ly6Chigh cells from CLP mice observed in ex vivo functional assays in C57BL/6J mice.
CONCLUSION: The splenic CD11b+Ly6Chigh myeloid populations expanded in survivors of CLP sepsis correspond to proliferating cells that have an increased metabolic demand and gene signatures consistent with M-MDSCs, a population known to have immunosuppressive capacity.
Multi-center study. The study explores Fraxinus which is an open source, software only, simple guiding system for bronchoscopy. The system provides 3D maps with centerline-to-target information extracted from preoperative computed tomography. The ability of the system to guide a user to a peripheral target lesion will be evaluated. During bronchoscopy any established method for diagnostic sampling is allowed. User Evaluation will be essential to decide if the Fraxinus VBN System is beneficial in a clinical setting.
A Phase 3, randomized, active-controlled, single-masked, parallel-group design study in pediatric subjects performed in the US. It is designed to evaluate the safety and anesthetic efficacy of one dose of AG-920 compared to Proparacaine. In this study, parent/legal guardians will provide informed consent (and where applicable, subjects will provide assent). Subjects who fulfill all the inclusion criteria and none of the exclusion criteria will be randomized in a 1:1 ratio to receive a single dose of AG 920 or Proparacaine into one (study) eye.

Each dose of AG-920 or Proparacaine HCl will consist of two drops in the study eye. After the completion of dosing, subjects will undergo an eye exam, and the ability to conduct that eye exam will be documented. Investigational medicinal product (IMP) dosing will be performed by the study staff.
The purpose of this study is to determine the areas of the brain responsible for paroxysmal hyperkinetic movement disorders. Paroxysmal hyperkinetic movement disorders have been clinically recognized for a long time, although the exact neurophysiological mechanism leading to paroxysms of hyperkinetic movement attacks is not well understood. Paroxysmal hyperkinetic movement disorders are heterogenous, and the exact mechanism may differ in each subcategory. In paroxysmal dyskinesias, the idiopathic forms of paroxysmal hyperkinetic movement disorders, it is speculated that transient functional abnormality at the cellular level occurs in the basal ganglia without organic irreversible damage. Ion channel dysfunction is an attractive hypothesis to explain such transient dysfunction. Some patients with paroxysmal hyperkinetic movement disorders have a psychogenic etiology.

A promising technique to evaluate physiological changes in the brain during an attack is ictal single photon emission computed tomography (SPECT) scanning. Ictal SPECT is a reliable method to detect a seizure focus during an epileptic seizure. We will utilize ictal SPECT scanning techniques during, and between attacks, and while they are simulating such attacks. The differential activation between the attacks of hyperkinetic movements and the voluntary movements may shed light on the regions of the brain and neurophysiological mechanisms responsible for generation of paroxysmal hyperkinetic movement disorders.
BACKGROUND: The adjuvant S-1 trial affirmed adjuvant chemotherapy for biliary tract cancer but excluded pT1N0 distal cholangiocarcinoma (DCC) according to the seventh edition of the American Joint Committee on Cancer (AJCC) classification. The introduction of tumor depth of invasion (DOI) for T-classification in the eighth edition complicates identifying DCC patients less likely to benefit from adjuvant chemotherapy.
METHODS: Our cohort consisted of 185 patients with DCC who underwent pancreaticoduodenectomy between 2002 and 2019. We compared clinicopathological factors and survival outcomes between pT1N0 patients in the seventh edition and those in the eighth edition. New DOI cutoffs for subdividing pT1N0 (8th edition) patients were evaluated to identify patients less likely to benefit from adjuvant chemotherapy.
RESULTS: Transitioning to the eighth edition increased in pT1N0 cases from eight to 46. The 5-year cumulative recurrence rates of them were 14.3% for the seventh edition and 28.3% for the eighth edition. We proposed a DOI cutoff of <2 mm, at which the 5-year cumulative recurrence rate was 11.5%.
CONCLUSION: The eighth AJCC classification revealed that a significant proportion of pT1N0 DCC patients were at risk for recurrence. A DOI cutoff of <2 mm may be considered to potentially improve patient selection for adjuvant chemotherapy.
The invention discloses a citrobacter freundii bacteriophage, a bacteriophage composition and application thereof, wherein the citrobacter freundii bacteriophage is named as PRF01, and has been preserved in the China general microbiological culture Collection center (China Committee for culture Collection of microorganisms) on the year 2022, the preservation address is North Chen Xili No. 1, no. 3 in the Korean region of Beijing city, and the preservation number is CGMCC No.45075. The invention also provides a phage composition, which comprises the citrobacter freundii phage. The citrobacter freundii bacteriophage and the bacteriophage composition can be applied to preparation of medicines for preventing and treating diseases caused by citrobacter freundii infection, aquatic feed additives or environmental disinfectants. The phage has excellent cracking performance on the citrobacter freundii, wide cracking spectrum and wide application range, has no side effect, and can effectively prevent and treat infection caused by the citrobacter freundii and various water problems caused by the massive proliferation of the pathogenic bacteria in water.
PCT No. PCT/SE92/00261 Sec. 371 Date Dec. 7, 1993 Sec. 102(e) Date Dec. 7, 1993 PCT Filed Apr. 22, 1992 PCT Pub. No. WO92/18169 PCT Pub. Date Oct. 29, 1992.Disclosed are emulsions for intravenous administration based on lipophilic iodized and/or bromated substances with emulsifiers and containing derivatives of cyclopenta-phenanthrene, wherein the weight ratio between emulsifier and derivative in the emulsion is between 10:1 and 1:2. These emulsions are intended for use as X-ray contrast agent, particularly for visibilizing the presence of tumors, metastases and the like in liver and spleen. The derivative of cyclopenta-phenanthrene is preferably cholesterol, phytosterol, sitosterol, sigmasterol and/or campesterol. The invention also relates to a method for preparing the emulsion and to the use of the emulsion in the preparation of an X-ray contrast medium for computed tomographic examinations.
In this crossover study, persons with motor incomplete cervical (C2-C8) spinal cord injury (AIS C-D) will be recruited from the Hospital District of Helsinki and Uusimaa. In the first period of the crossover study, other part of the participants will get technological-assisted upper extremity rehabilitation, while the other part of the participants continue their normal lives. The first period is followed by 4-week wash-out period. In the second period, roles of the participants will be switched. The rehabilitation phase lasts for 6 weeks with 3 weekly sessions, each therapy session including at least 30 minutes of technological-assisted upper extremity rehabilitation. Rehabilitation includes passive, active and resistance exercises, and will be carried out by using AMADEO, PABLO and/or DIEGO devices made by Tyromotion.
The present invention is directed to a method of inhibiting cholesterol transport through the intestinal lumen of a subject. The method comprises administering an intestinal alkaline phosphatase inhibitor to the subject. The inhibition of intestinal alkaline phosphatase prevents transport of exogenous cholesterol through the intestinal lumen and therefore decreases plasma levels of cholesterol. The invention further provides a method of screening for agents which inhibit cholesterol transport. This method comprises expressing intestinal alkaline phosphatase in a host cell, exposing the host cell to an agent and cholesterol, and determining whether the cholesterol is transported into the host cell. Since intestinal alkaline phosphatase mediates cholesterol transport into the cell, an agent that inhibits the expressed intestinal alkaline phosphatase (or inhibits the expression of intestinal alkaline phosphatase), will inhibit cholesterol transport.
PURPOSE: A composition containing red ginseng extract is provided to reduce side effects of ototoxic drug-induced vestibular dysfunction and to treat infectious diseases. CONSTITUTION: A pharmaceutical composition for preventing or treating ototoxic drug-induced vestibular dysfunction contains red ginseng extract as an active ingredient. The extract is prepared using water, low carbon number alcohol of 1-4 carbon atoms, or a mixture solvent thereof. The ototoxic drug is antibiotics, anticancer drug, or diuretic. The antibiotics include streptomycin, kanamycin, gentamycin, neomycin, amikacin, tobramycin, or netilmycin. An aid for suppressing the side effects of vestibular dysfunction-related antibiotics contains the extract as an active ingredient. A food composition for preventing or treating vestibular dysfunction contains the red ginseng extract as an active ingredient.
ETHNOPHARMACOLOGICAL RELEVANCE: Papaver rhoeas L. (P. rhoeas) is used to treat a wide range of pathologies. But there is no data on the anti-struvite, anti-inflammatory, analgesic, and anti-depressant effects of root and leaf extracts from this medicinal plant.
AIM OF THE STUDY: This study aimed to chemically characterize and determine the antidepressant, analgesic, anti-inflammatory, and anti-struvite activities of the root extract (RE) and leaf extract (LE) of P. rhoeas, a wild plant.
MATERIALS AND METHODS: The extraction of secondary metabolites and phytochemical screening were carried out using standard methods. The anti-struvite effect of our samples was assessed by Fourier transform infrared spectroscopy (FT-IR) and microscopic observation. For the anti-inflammatory impact, we used the carrageenan-induced paw edema technique in rats. To assess the analgesic effect of the extracts, we recorded the resulting abdominal contraction after intraperitoneal (IP) acetic acid injection. Finally, we assessed the antidepressant effect by conducting the Forced Swimming Test (FST).
RESULTS: Phytochemical screening results revealed the presence of phenols, flavonoids, saponins, tannins, coumarins, terpenoids, and alkaloids. Extraction results confirmed that our extracts were rich in secondary metabolites. Both P. rhoeas extracts limited struvite crystal development by reducing the size and number of crystals, as indicated by FT-IR analysis and microscopic observation. Additionally, the anti-struvite effects of the LE sample were greater than those of the RE sample. The results of the anti-inflammatory capacity of our extracts demonstrate the maximum inhibition of carrageenan-induced edema following 6 h (T6) of injection, ranging from 72.73 ± 7.7% for LE (400 mg/kg) to 95.45 ± 6.42% for the RE sample (400 mg/kg). On the other hand, the results for analgesic activity showed that the number of abdominal contractions in rats treated with RE and LE ranged from 11 ± 1.73 for RE (400 mg/kg) to 18 ± 1.50 for LE (200 mg/kg), while that of aspirin was 10.33 ± 0.57. Furthermore, the FST results show that the immobility time in rats treated with RE and LE varied from 91.98 ± 4.24 s for LE-treated rats (300 mg/kg) to 123.54 ± 7.83 s for RE-treated rats (150 mg/kg).
CONCLUSION: Based on these results, the roots and leaves of the studied plant can be considered a significant source of biologically active molecules for use in the pharmaceutical industry.
Subject received Manganese primed anti-PD-1 antibody, nab-paclitaxel and gemcitabine every 3 weeks until achieving a second assessable stable disease or up to a maximum of 12 cycles. Treatment continued until progressive disease, development of unacceptable toxicity, or withdrawal of consent.
Patients receive ivermectin PO QD on days 1-3, 8-10, and 15-17. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also receive balstilimab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 35 cycles in the absence of disease progression or unacceptable toxicity.
The invention relates to pharmaceutical compositions for treating or preventing infection by coronaviruses as well as coronavirus mediated disease, e.g., respiratory disorders. The disclosure provides treatments comprising immune cells, such as natural killer cells, and antibodies or vaccines that target coronaviruses. Compositions and kit-of-parts comprising said immune cells and antibodies or vaccines are also provided. The disclosure also provides engineered immune cells expressing a chimeric antigen receptor (CAR). Such CAR expressing cells are useful for treatment. Exemplary viral targets of the present invention include the coronavirus spike protein, in particular evolutionary conserved epitopes thereof.
1331830 Agitator mills SOCO BASEL AG 16 Dec 1971 [17 Dec 1970] 58383/71 Heading B2A [Also in Division A5] A mill for use in extracting therapeutic substances from spleen tissue (see Division A5) comprises a fixed, cylindrical mill casing 40, filled with a grinding material charge of glass balls 97, of maximally 5 mm. diameter, and provided with a stirrer which passes through the grinding material charge and is connected to an external drive inlet pipeline 60, for introduction of the slurry entering one end of the casing and an oulet pipeline 58, for removal of -the suspension, equipped with a sieve device 57, starting from the other end of the casing. The jacket of the casing is double-walled, having an outer wall 43, and an inner wall 44, so that an annular cavity 45 is left, through which cooling water flows via an inlet attachment 46 and an outlet attachment to a sink 23. A grinding shaft 51, on which six grinding discs 52 and 53 are mounted, is rotatably fixed in bearings in the interior of the grinding space 47 and coaxially of the cylinder axis 41, and the shaft has a stub end at the outlet end face 56 and is carried, at the input end face 54, in a pressure tight and liquid-tight passage 55, through which it passes and is coupled to an electric drive motor 96. The sieve device 57 opens into an outlet attachment 58 and possesses a pipe section 70 which is pushed coaxially on to the end of the shaft 51 and is itself carried in a liquid-tight rotary bearing 71 having a bearing plate 72 which, together with the end face 56 and the inner wall 44, encloses a space 73 from which the outlet attachment 58 starts and in which the bearing 74 for the shaft 51 is accommodated. A split disc 75 is mounted on the shaft 51 so that the disc cannot twist and the pipe section 70 is attached to it. Pipe section 70 has three further split discs 76, 77 and 78 mounted thereon and possesses perforations 87 in the region of gaps 80 and 81 within which annular discs 85, 86 are mounted on the pipe section 70 in such a way that they cannot twist and their wider peripheral rings 82, 92 leave narrow annular gaps 83, 84 and 91, 94.
Operations technique on the abdominal aorta. Aorta-femoral bypass. Medication: after surgery all patients are prescribed long-term aspirin (100 mg daily) and clopidogrel for 3 months (75 mg daily).
We present a rare case of low titre GAD65 antibody-associated autoimmune encephalitis and status epilepticus in a young woman. She initially presented with left arm dystonic movements, contractures and status epilepticus. Due to the concern of autoimmune encephalitis and seizures, the patient received intravenous immunoglobulin empirically. After the detection of low serum GAD65 antibodies, the patient underwent immunomodulation therapy with significant improvement. This case demonstrated that in autoimmune encephalitis, it is important to monitor serum GAD65 antibodies levels and consider immunotherapy, despite mildly elevated serum levels. The patient's history of left arm dystonic movements without impaired awareness may have been due to limb dystonia, a presenting symptom of stiff person syndrome (SPS), despite SPS more commonly affecting axial muscles. This case further demonstrates that GAD65 antibody-related syndromes can manifest with different neurological phenotypes including co-occurrence of epilepsy with possible focal SPS despite low GAD65 antibodies titres.
Patients receive oral erlotinib hydrochloride once daily on days 1-14, panitumumab IV over 30-90 minutes on day 1, and irinotecan hydrochloride IV over 90 minutes on day 1. Treatment repeats every 2 weeks in the absence of disease progression or unacceptable toxicity.